Heart Failure

Heart failure occurs when the heart cannot pump as much blood as the body requires. This ineffective pumping can lead to enlargement of the heart as the myocardium works harder pump the same amount of blood. Heart failure may be caused by defects in the myocardium, such as an a heart attack infarct, or due to structural issues such as severe heart valve regurgitation. Heart failure can be divided into HF with preserved ejection fraction (HFpEF), and HF with reduced ejection fraction (HFrEF). The disease is further divided into four New York Heart Association (NYHA) classes. Stage IV heart failure is when the heart is completely failing and requires a heart transplant or hemodynamic support from a left ventricular assist device (LVAD).

RSS icon
Early clinical evaluation of the Alleviant System to create no-implant interatrial shunts to treat heart failure patients with preserved and reduced ejection fraction (HFpEF and HFrEF) demonstrated procedural safety and feasibility with a promising efficacy signal through six months.

Key interventional cardiology takeaways from the SCAI 2022 conference

The key interventional cardiology takeaways from sessions presented at the Society for Cardiovascular Angiography and Interventions (SCAI) 2022 annual meeting.

cocaine heart failure HFrEF LVEF hospitalizations beta-blockers hypertension cardiology

How cocaine use affects outcomes for hospitalized heart failure patients

When cocaine users are hospitalized for heart failure, what should physicians expect? Are beta-blockers an effective treatment strategy? 

Thumbnail

EHR alerts boost care for patients with HFrEF

Simple EHR alerts helped one health system get more guideline-recommended medications to its heart failure patients.

Thumbnail

LVAD patients spend nearly 1 in 4 days seeking care — is there a more effective way?

The study's authors noted that LVADs consistently lead to strong outcomes, but improvements are still needed to reduce the burden on patients. 

Empagliflozin may reverse vascular aging, lower CVD risk

The SGLT2 inhibitor is already known as an effective medication for both type 2 diabetes and heart failure.

TPV valves, CTO PCI and more: SCAI 2022 updates for interventional cardiologists

The first two days of SCAI 2022 were jam-packed with innovative technologies and late-breaking research.

David Bennett

How did the pig heart transplant patient die? A preventable infection may be to blame

The genetically modified pig heart appears to have been infected with a porcine virus, according to the surgeon who performed the initial transplant. 

transcatheter aortic valve replacement (TAVR) procedure guided by CT fusion imaging on a patient with heart failure and a blood clot

Cardiologists and surgeons perform first TAVR using CT imaging guidance on HF patient with blood clot

“We believe this case is potentially groundbreaking," one interventional cardiologist said. 

Displaying 257 - 264 of 1270

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.